Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

PPBT
Purple Biotech Ltd.
stock NASDAQ ADR

Market Open
Nov 7, 2025 11:55:59 AM EST
0.7500USD-0.120%(0.0000)252,494
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Nov 7, 2025 9:23:30 AM EST
0.7347USD-2.040%(-0.0153)8,531
After-hours
Nov 6, 2025 4:44:30 PM EST
0.7381USD-1.587%(-0.0119)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 6, 2022
07:30AM EST  Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Ori Hershkovitz, a long-time life sciences industry investor, to its Board of Directors.   GlobeNewswire Inc
Dec 9, 2021
07:30AM EST  Purple Biotech Appoints Senior Business Development Executive   GlobeNewswire Inc
Dec 6, 2021
07:50AM EST  Purple Biotech Initiates Part 2 Of Ongoing Phase 1/2 Trial Evaluating NT219 For Treatment Of Multiple Cancers   RTTNews
07:33AM EST  Purple Biotech Announces Initiation Of Part 2 Of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 For Treatment Of Multiple Cancers Supporting Potential Expansion Of Clinical Program   Benzinga
07:30AM EST  Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Cancer or Colorectal Adenocarcinoma   GlobeNewswire Inc
Nov 3, 2021
07:30AM EDT  Purple Biotech to Present at the Jefferies London Healthcare   GlobeNewswire Inc
Oct 26, 2021
08:28AM EDT  Purple Biotech Expands Existing Research Agreement At The University Of Texas MD Anderson Cancer Center And Will Evaluate Potential Efficacy Of Immuno-Oncology In Combination With NT219   Benzinga
08:27AM EDT  Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies   GlobeNewswire Inc
Oct 22, 2021
06:41AM EDT  Purple Biotech Earlier Highlighted Publication In 'Nature Cancer' That Showed Underlying Mechanism Of therapeutic Resistance Of Cancer Cells, Role Of Insulin Pathway On Epithelial Growth Factor Receptor Therapy   Benzinga
06:00AM EDT  Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy   GlobeNewswire Inc
Sep 13, 2021
07:00AM EDT  One Advanced Pancreatic Cancer Patient Demonstrated a Partial Response in First Dose Cohort in Combination with Nivolumab   GlobeNewswire Inc
Aug 5, 2021
08:49AM EDT  Purple Biotech Reports H1 EPS $(0.59) Up from $(4.63) YoY   Benzinga
Jun 4, 2021
10:35AM EDT  Purple Biotech ASCO Presentation Fails to Cheer Investors   Benzinga
10:12AM EDT  Mid-Morning Market Update: Markets Open Higher; US Economy Adds 559,000 Jobs in May   Benzinga
08:04AM EDT  Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting   Benzinga
08:00AM EDT  Partial Response Observed in aPatient with Refractory Gastroesophageal Junction Cancer   GlobeNewswire Inc
May 26, 2021
07:38AM EDT  Purple Biotech to Present at the Jefferies Virtual Healthcare   GlobeNewswire Inc
May 20, 2021
07:00AM EDT  Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted   GlobeNewswire Inc
May 19, 2021
07:18AM EDT  Purple Biotech Appoints Suzana Nahum-Zilberberg To Board   RTTNews
07:00AM EDT  Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Suzana Nahum-Zilberberg, a seasoned biopharmaceutical Industry executive, to its Board of Directors.   GlobeNewswire Inc
Apr 23, 2021
08:07AM EDT  Purple Biotech Announces Dosing Of First Patient In Phase 1b/2 Clinical Trial Of CM24 In Advanced Cancer Patients   Benzinga
08:00AM EDT  Preliminary Data from First Part of Study Anticipated in Second Half of 2021   GlobeNewswire Inc
Apr 13, 2021
08:23AM EDT  Purple Biotech Highlights Presentation Of NT219 Mechanism Of Action Data At AACR Annual Meeting   Benzinga
08:17AM EDT  Purple Biotech Presents Additional Mechanism of Action Data for   GlobeNewswire Inc
Mar 19, 2021
08:02AM EDT  Purple Biotech Reports Initiation Of Phase 1b/2 Trial Of CM24 For Treatment Of Multiple Advanced Cancers   Benzinga
08:00AM EDT  Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb   GlobeNewswire Inc
Mar 11, 2021
08:02AM EST  Purple Biotech to Present Additional Mechanism of Action Data for   GlobeNewswire Inc
Mar 3, 2021
07:00AM EST  Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert   GlobeNewswire Inc
Mar 2, 2021
07:12AM EST  Purple Biotech Reports FY20 Second Half Net Loss Per Share of $0.48, Compared To A Net Loss of $1.70 YoY   Benzinga
07:00AM EST  Purple Biotech Ltd. (Purple Biotech) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six and 12-months ended December 31, 2020.   GlobeNewswire Inc
Feb 12, 2021
12:19PM EST  Purple Biotech Shares Move Higher; Kitov Pharmaceuticals (Former Company Name) To Be Issued U.S. Patent 'CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME'   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 18, 2021
07:42AM EST  Purple Biotech Ltd. (Purple Biotech) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple Biotech management team will present a corporate overview at the B. Riley Oncology Investor Conference, being held virtually January 20-21, 2021.   GlobeNewswire Inc
Jan 4, 2021
09:40AM EST  Virtual Bell-Ringing Ceremony in Celebration of Companys Recent Name Change to Purple Biotech   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC